Trial
NCT02069340
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
UnknownWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Condition
Malignant Neoplasm
Intervention
zoledronic acid
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-11